drugset

drugset / Trial / NCT04392037

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

NCT04392037 ↗

Phase 2 Active not recruiting 60 enrolled Amsterdam UMC, location VUmc Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Timeline

Start: 2021-02-17
Primary completion: 2027-12
Completion: 2027-12

Publications

Korst CLBM, Plattel W, de Kort EA, Smits F, Croockewit AJ, Levin MD, Westerman M, de Weerdt O, Nijhof IS, Wegman J, Smit N, Verkleij CPM, Mutis T, Nasserinejad K, Kerstiens R, van der Klift M, Franssen LE, de Ruijter MEM, Groen K, van der Spek E, Roeloffzen WWH, Zweegman S, van de Donk NWCJ. Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2026 Jan;13(1):e30-e40. doi: 10.1016/S2352-3026(25)00298-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	50 mg	Oral
Subject	Dexamethasone	Small molecule	20 mg	Oral
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Iberdomide	Small molecule	1.6 mg	Oral

Indications